

Nigel J Garrett

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4564426/nigel-j-garrett-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

69
papers

2,300
citations

22
h-index

47
g-index

75
ext. papers

3,258
ext. citations

8.9
avg, IF

4.65
L-index

#	Paper	IF	Citations
69	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. <i>Nature</i> , 2014 , 509, 55-62	50.4	537
68	Genital inflammation and the risk of HIV acquisition in women. <i>Clinical Infectious Diseases</i> , 2015 , 61, 260-9	11.6	239
67	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). <i>Lancet, The</i> , 2018 , 392, 232-243	40	170
66	Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. <i>Nature Medicine</i> , 2015 , 21, 1332-6	50.5	154
65	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. <i>Journal of Virology</i> , 2016 , 90, 76-91	6.6	151
64	The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	66
63	Integrin β expression on peripheral blood CD4 T cells predicts HIV acquisition and disease progression outcomes. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	62
62	Ability to develop broadly neutralizing HIV-1 antibodies is not restricted by the germline Ig gene repertoire. <i>Journal of Immunology</i> , 2015 , 194, 4371-8	5.3	58
61	The impact of the COVID-19 lockdown on HIV care in 65 South African primary care clinics: an interrupted time series analysis. <i>Lancet HIV,the</i> , 2021 , 8, e158-e165	7.8	55
60	HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2018 , 14, e1006987	7.6	49
59	Beyond syndromic management: Opportunities for diagnosis-based treatment of sexually transmitted infections in low- and middle-income countries. <i>PLoS ONE</i> , 2018 , 13, e0196209	3.7	45
58	Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research. <i>Lancet HIV,the</i> , 2018 , 5, e400-e404	7.8	44
57	Prior infection with SARS-CoV-2 boosts and broadens Ad26.COVS immunogenicity in a variant-dependent manner. <i>Cell Host and Microbe</i> , 2021 , 29, 1611-1619.e5	23.4	38
56	Rapid disease progression in HIV-1 subtype C-infected South African women. <i>Clinical Infectious Diseases</i> , 2014 , 59, 1322-31	11.6	35
55	Point-of-Care HIV Viral Load Testing: an Essential Tool for a Sustainable Global HIV/AIDS Response. <i>Clinical Microbiology Reviews</i> , 2019 , 32,	34	34
54	Diagnostic Accuracy of the Point-of-Care Xpert HIV-1 Viral Load Assay in a South African HIV Clinic. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016 , 72, e45-8	3.1	34
53	Point-of-care HIV viral load testing combined with task shifting to improve treatment outcomes (STREAM): findings from an open-label, non-inferiority, randomised controlled trial. <i>Lancet HIV,the</i> , 2020 , 7, e229-e237	7.8	31

52	The arrival of a true point-of-care molecular assay-ready for global implementation?. <i>The Lancet Global Health</i> , 2015 , 3, e663-4	13.6	30
51	Point-of-care viral load testing and differentiated HIV care. <i>Lancet HIV,the</i> , 2018 , 5, e8-e9	7.8	27
50	Case report: mechanisms of HIV elite control in two African women. <i>BMC Infectious Diseases</i> , 2018 , 18, 54	4	26
49	IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody. <i>PLoS Pathogens</i> , 2019 , 15, e1008064	7.6	25
48	Clinic flow for STI, HIV, and TB patients in an urban infectious disease clinic offering point-of-care testing services in Durban, South Africa. <i>BMC Health Services Research</i> , 2018 , 18, 363	2.9	20
47	South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on β for replication. <i>Retrovirology</i> , 2015 , 12, 54	3.6	18
46	Diagnostic accuracy of the Xpert CT/NG and OSOM Trichomonas Rapid assays for point-of-care STI testing among young women in South Africa: a cross-sectional study. <i>BMJ Open</i> , 2019 , 9, e026888	3	17
45	Residual T cell activation and skewed CD8+ T cell memory differentiation despite antiretroviral therapy-induced HIV suppression. <i>Clinical Immunology</i> , 2018 , 195, 127-138	9	17
44	Randomized Cross-Sectional Study to Compare HIV-1 Specific Antibody and Cytokine Concentrations in Female Genital Secretions Obtained by Menstrual Cup and Cervicovaginal Lavage. <i>PLoS ONE</i> , 2015 , 10, e0131906	3.7	17
43	V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity. <i>Cell Reports</i> , 2018 , 25, 3123-3135.e6	10.6	17
42	HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth. <i>Cell Host and Microbe</i> , 2018 , 24, 593-599.e3	23.4	17
41	Acceptability of Early Antiretroviral Therapy Among South African Women. <i>AIDS and Behavior</i> , 2018 , 22, 1018-1024	4.3	16
40	Protocol for a randomised controlled implementation trial of point-of-care viral load testing and task shifting: the Simplifying HIV TREATment and Monitoring (STREAM) study. <i>BMJ Open</i> , 2017 , 7, e017507	3	16
39	Comparative cost analysis of point-of-care versus laboratory-based testing to initiate and monitor HIV treatment in South Africa. <i>PLoS ONE</i> , 2019 , 14, e0223669	3.7	15
38	Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women. <i>Aids</i> , 2016 , 30, 1005-14	3.5	15
37	HPV infection and the genital cytokine milieu in women at high risk of HIV acquisition. <i>Nature Communications</i> , 2019 , 10, 5227	17.4	15
36	Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review. <i>Journal of Infectious Diseases</i> , 2021 , 223, 370-380	7	15
35	Effect of Antiretroviral Therapy on the Memory and Activation Profiles of B Cells in HIV-Infected African Women. <i>Journal of Immunology</i> , 2017 , 198, 1220-1228	5.3	12

34	Understanding how community antiretroviral delivery influences engagement in HIV care: a qualitative assessment of the Centralised Chronic Medication Dispensing and Distribution programme in South Africa. <i>BMJ Open</i> , 2020 , 10, e035412	3	12
33	HIV-1 Superinfection Resembles Primary Infection. <i>Journal of Infectious Diseases</i> , 2015 , 212, 904-8	7	11
32	Replication Capacity of Viruses from Acute Infection Drives HIV-1 Disease Progression. <i>Journal of Virology</i> , 2017 , 91,	6.6	10
31	HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015 , 68, 55-61	3.1	10
30	Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. <i>PLoS ONE</i> , 2020 , 15, e0226803	3.7	10
29	Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial. <i>BMJ Open</i> , 2019 , 9, e030283	3	8
28	Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial. <i>BMJ Open</i> , 2020 , 10, e042247	3	8
27	Computational analysis of antibody dynamics identifies recent HIV-1 infection. <i>JCI Insight</i> , 2017 , 2,	9.9	8
26	Review of preventative HIV vaccine clinical trials in South Africa. <i>Archives of Virology</i> , 2020 , 165, 2439-2452		7
25	Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study.. <i>Lancet, The</i> , 2022 , 399, 1141-1153	40	7
24	Assessing a diagnosis tool for bacterial vaginosis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020 , 39, 1481-1485	5.3	6
23	Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study. <i>Lancet HIV,the</i> , 2021 , 8, e216-e224	7.8	6
22	Cost-effectiveness of adoption strategies for point of care HIV viral load monitoring in South Africa. <i>EClinicalMedicine</i> , 2020 , 28, 100607	11.3	4
21	Clinic-Based Evaluation of a Point-of-Care Creatinine Assay to Screen for Renal Impairment Among HIV-Positive Patients Receiving Tenofovir Disoproxil Fumarate. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018 , 77, e36-e39	3.1	4
20	Antibody Isotype Switching as a Mechanism to Counter HIV Neutralization Escape. <i>Cell Reports</i> , 2020 , 33, 108430	10.6	4
19	HIV treatment outcomes among people with initiation CD4 counts >500 cells/ μ L after implementation of Treat All in South African public clinics: a retrospective cohort study. <i>Journal of the International AIDS Society</i> , 2020 , 23, e25479	5.4	3
18	ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection. <i>PLoS Pathogens</i> , 2021 , 17, e1010046	7.6	3
17	Short Communication: Early Antiretroviral Therapy Is Associated with Better Viral Suppression and Less HIV Drug Resistance After Implementation of Universal Treatment in South Africa. <i>AIDS Research and Human Retroviruses</i> , 2020 , 36, 297-299	1.6	2

16	Recent Semen Exposure Impacts the Cytokine Response and Bacterial Vaginosis in Women. <i>Frontiers in Immunology</i> , 2021 , 12, 695201	8.4	2
15	Low CD4 count and educational status predict abnormal cervical smears amongst HIV-positive women initiating antiretroviral therapy in South Africa. <i>Southern African Journal of HIV Medicine</i> , 2020 , 21, 1045	1.4	1
14	Differentiated service delivery for people using second-line antiretroviral therapy: clinical outcomes from a retrospective cohort study in KwaZulu-Natal, South Africa. <i>Journal of the International AIDS Society</i> , 2021 , 24 Suppl 6, e25802	5.4	1
13	Immunological Correlates of the HIV-1 Replication-Competent Reservoir Size. <i>Clinical Infectious Diseases</i> , 2021 , 73, 1528-1531	11.6	1
12	Genital HSV-1 DNA detection is associated with a low inflammatory profile in HIV-uninfected South African women. <i>Sexually Transmitted Infections</i> , 2021 , 97, 33-37	2.8	1
11	Impact of point-of-care testing and treatment of sexually transmitted infections and bacterial vaginosis on genital tract inflammatory cytokines in a cohort of young South African women. <i>Sexually Transmitted Infections</i> , 2021 , 97, 555-565	2.8	1
10	Temporal Changes in Vaginal Microbiota and Genital Tract Cytokines Among South African Women Treated for Bacterial Vaginosis. <i>Frontiers in Immunology</i> , 2021 , 12, 730986	8.4	1
9	Antimicrobial Resistance Mechanisms, Multilocus Sequence Typing, and NG-STAR Sequence Types of Diverse <i>Neisseria gonorrhoeae</i> Isolates in KwaZulu-Natal, South Africa. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0075921	5.9	1
8	Pre-infection plasma cytokines and chemokines as predictors of HIV disease progression.. <i>Scientific Reports</i> , 2022 , 12, 2437	4.9	1
7	High-Resolution Melting Analysis to Detect Antimicrobial Resistance Determinants in South African Clinical Isolates and Specimens.. <i>International Journal of Microbiology</i> , 2022 , 2022, 9094328	3.6	0
6	Simplifying TREATment and Monitoring for HIV (STREAM HIV): protocol for a randomised controlled trial of point-of-care urine tenofovir and viral load testing to improve HIV outcomes. <i>BMJ Open</i> , 2021 , 11, e050116	3	0
5	Acceptability of point-of-care viral load testing to facilitate differentiated care: a qualitative assessment of people living with HIV and nurses in South Africa. <i>BMC Health Services Research</i> , 2020 , 20, 1081	2.9	0
4	HIV susceptibility in women: The roles of genital inflammation, sexually transmitted infections and the genital microbiome. <i>Journal of Reproductive Immunology</i> , 2021 , 145, 103291	4.2	0
3	Protocol for a randomised feasibility study of Point-Of-care HIV viral load testing to Enhance Re-suppression in South Africa: the POWER study. <i>BMJ Open</i> , 2021 , 11, e045373	3	0
2	Conceptualising implementation strategies in HIV research - AuthorsSreply. <i>Lancet HIV,the</i> , 2020 , 7, e382-383	7.8	1
1	Performance of TaqMan probes for the detection of sexually transmitted infections in South African women. <i>African Journal of Laboratory Medicine</i> , 2021 , 10, 1124	0.9	0